Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT07618754
Starting soon Not applicable

Shame, Resilience and Well-being After Intimate Partner Violence: an Intervention Study With Replicated Single-Subject Design.

NCT07618754 · tracked via the Priya Life Science Sweden tracker
Sponsor
Uppsala University
Phase
Not applicable
Started
2026-06
Last updated
2026-06-01

Condition(s) studied

Intimate Partner ViolenceResilience, Psychological

Investigational drug(s) / intervention(s)

Resilience enhancing intervention, individual formatResilience enhancing intervention, group format

Resilience enhancing intervention, individual format: A 4-step, Resilience-focused intervention based on the Resilience Portfolio Model, administered in individual format.

Resilience enhancing intervention, group format: A 4-step, Resilience-focused intervention based on the Resilience Portfolio Model, administered in group format.

Study summary

The EMBER protocol is a health care method that is designed to increase resilience, in order to improve well-being and overall health in women who have experienced violence by a partner. This study explores whether the EMBER intervention works in this way. Eight participants will take part in the EMBER program and complete questionnaires every week during the intervention. The researchers will compare the timeline for the intervention to how resilience levels change. They will also check whether changes in resilience are linked to changes in health and well-being.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * subjected to IPV within 2 years prior to enrollment * capable of completing questionnaires using a mobile phone * intention to complete intervention * identifies as female Exclusion Criteria: * ongoing severe IPV * ongoing severe substance use * psychosis * moderate to severe suicidality * ongoing psychological intervention in other facility

Primary outcome measure(s)

  • Resilience - Psychological Endurance — Bi-weekly from enrollment 2-6 weeks prior to start of intervention, to completion of the intervention (intervention phase A and/or C). Follow-up 6 weeks post-intervention.
    The self assessment questionnaire Psychological Endurance Scale (range 6-24, higher value indicates higher endurance) is completed bi-weekly using a mobile application. Data will be analyzed with a combination of visual and statistical analyses.
  • Resilience - Subjective Social Support — Bi-weekly from enrollment 2-6 weeks prior to start of intervention to completion of the intervention (intervention phase A and/or C). Follow-up 6 weeks post-intervention.
    The Oslo Subjective Social Support Scale - 3 items (range 3-14, higher value indicates higher level of social support) is completed bi-weekly using a mobile application. Data will be processed using a combination of visual and statistical analyses.
  • Resilience - Meaning Making — Bi-weekly from enrollment 2-6 weeks prior to start of the intervention, to completion of the intervention (intervention phase A and/or C). Follow-up 6 weeks post-intervention.
    The MAPS - Meaningfulness subscale (range 5-25, higher value indicating higher meaningfulness) is completed by the subjects bi-weekly. Data is processed using a combination of statistical and visual analyses.

Trial sites (1)

FacilityCityRegionStatus
Uppsala University Hospital Uppsala Uppsala County

More Uppsala University trials in Sweden

Minimal Invasive Scoliosis or Open Surgery Starting soon
Validation of Pediatric Sleep Questionnaire on a Swedish Cohort Recruiting
Validation of the Swedish Translation of a Brief Shame Measure, the External and Internal Shame Scale Recruiting
Improved Oral Health in Head and Neck Cancer Survivors Recruiting
Fibromyalgia and Sleep Disorder Treatment Enrolling by invitation

Other trials for the same condition

Resilience and Recovery After Intimate Partner Violence - Evaluation of the EMBER-IPV Protocol Starting soon
How a Resilience-Focused Intervention is Perceived by Women Subjected to Domestic Violence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07618754 on ClinicalTrials.gov ↗ ← All trials in Sweden